Over the last three days it has been thin for 52-week lows, but a good market drop sure brings a reminder to the wall of shame. Here are some of today’s key 52-week lows.
Altus Pharmaceuticals (NASDAQ: ALTU) tanked after Phase III cystic fibrosis tests failed to please on all fronts.
Apex Silver Mines (AMEX: SIL) fell nearly 40% after earnings disappointed. At least they can use those mines for mushroom growth if they don’t find silver.
Constellation Energy (NYSE: CEG) Fell over $11.00 to new 52-week lows after an analyst raised more questions about the company.
Comverge (NASDAQ: COMV) fell on its sword after missing estimates and lowering targets on regulatory changes at a major client.
Edison International NYSE: EIX) hit another 52-week low after selling $400M in bonds.
Horsehead Holdings (NASDAQ: ZINC) hit new lows as earnings failedto give any inspiration. Shares closed almost 5% under the prior rangeof $9.04 to $26.14. With this stock name we could think of two newnicknames for the company, but we’ll be nice.
Mirant (NYSE: MIR) Followed Edison to join the wall of shame again down 2% under prior 52-week lows.
Zoltek Technologies (NASDAQ: ZOLT) was a shocker of an earningsdisappointment with wind power under question. Shares fell to $15.52,well under the old $17.75 to $48.78 52-week range.
Jon C. Ogg August 12, 2008
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.